Literature DB >> 439249

Outpatient evaluation of patients with calcium urolithiasis.

G W Drach, R Perin, S Jacobs.   

Abstract

Eighty patients with proved calcium urolithiasis participated in an outpatient study designed to define the most likely metabolic problem related to the cause of the stone disease. Diagnostic categories included absorptive hypercalciuria (33 patients), renal leak hypercalciuria (20 patients), hypomagnesiumuria (27 patients), hyperuricemia and hyperuricuria (16 patients), hyperoxaluria (15 patients), normal stone-former (4 patients), renal tubular acidosis (2 patients) and suspicion of hyperparathyroidism (7 patients). Of the 80 patients 40 had more than 1 defect. Patients with a high suspicion of hyperparathyroidism were excluded from the study. Based on these criteria treatment plans incorporating medications, diet or both were instituted. Of 21 patients observed for greater than 2 years 90 per cent have shown no new stone disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 439249     DOI: 10.1016/s0022-5347(17)56881-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Pattern of urolithiasis in a general hospital. A prospective study.

Authors:  M S Khalifa; A al Shazly; P C Reavey
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

2.  [Peroral calcium administration test with free diet in idiopathic calcium nephrolithiasis--possibilities and limits].

Authors:  B Hess; A Winter; K Gautschi; U Binswanger
Journal:  Klin Wochenschr       Date:  1986-10-15

3.  Urolithiasis in Kuwait.

Authors:  N S Khalifa; A A Gabal; M Shihab
Journal:  Int Urol Nephrol       Date:  1986       Impact factor: 2.370

4.  Oxalate status in stone-formers. Two distinct hyperoxaluric entities.

Authors:  M Hatch
Journal:  Urol Res       Date:  1993-01

5.  Some features of paediatric urolithiasis in a group of Syrian children.

Authors:  S Hadidy; M Z Shammaa; A Kharma
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.